Two HIV-infected patients had recurrent cryptococcal meningitis (CM) despite treatment with fluconazole and immune reconstitution with combination antiretroviral therapy (CART). Following treatment of CM with fluconazole, lumbar puncture should be performed either after completion of induction treatment for CM or before starting CART, in order to confirm cerebrospinal fluid sterility.
HakimJG, GangaidzoIT, HeydermanRS, Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. AIDS2000;14:1401–7
2.
SaagMS, GraybillRJ, LarsenRA, Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis2000;30:710–8
3.
MasurH, KaplanJE, HolmesKK. Guidelines for preventing opportunistic infections among HIV-infected persons – 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med2002;137:435–78
4.
BrouwerAE, RajanuwongA, ChierakulW, Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet2004;363:1764–7
5.
SchaarsCF, MeinjtesGA, MorroniC, PostFA, MaartensG. Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. BMC Infect Dis2006;97:175–6
6.
MwabaP, MwansaJ, ChintuC, Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J2001;77:769–73
7.
KambuguA, MeyaDB, RheinJ, Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis2008;46:1694–701
8.
MussiniC, PezzottiP, MiroJM, Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis2004;38:565–71
9.
VibhagoolA, SungkanuparphS, MootsikapunP, Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis2003;36:1329–31
10.
KirkO, ReissP, Uberti-FoppaC, Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med2002;137:239–50
11.
HeydermanRS, GangaidzoIT, HakimJG, Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe. Clin Infect Dis1998;26:284–9
12.
BicanicT, MeintjesG, WoodR, Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis2007;45:76–80
13.
SaagMS, PowderlyWG, CloudGA, Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med1992;326:83–9
14.
LarsenRA, LealMA, ChanLS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med1990;113:183–7
15.
KingMD, PerlinoCA, CinnamonJ, JerniganJA. Paradoxical recurrent meningitis following therapy of cryptococcal meningitis: an immune reconstitution syndrome after initiation of highly active antiretroviral therapy. Int J STD AIDS2002;13:724–6
16.
BoelaertJR, GodderisKH, VanopdenboschLJ, CasselmanJW. Relapsing meningitis caused by persistent cryptococcal antigens and immune reconstitution after the initiation of highly active antiretroviral therapy. AIDS2004;18:1223–4
